1-[(benzyloxy)carbonyl]-4-ethyl-2,5-dihydro-1H-pyrrole-3-carboxylic acid manufacturers
|
| 1-[(benzyloxy)carbonyl]-4-ethyl-2,5-dihydro-1H-pyrrole-3-carboxylic acid Basic information |
| 1-[(benzyloxy)carbonyl]-4-ethyl-2,5-dihydro-1H-pyrrole-3-carboxylic acid Chemical Properties |
Boiling point | 452.3±45.0 °C(Predicted) | density | 1.267±0.06 g/cm3(Predicted) | pka | 4.28±0.20(Predicted) | InChI | InChI=1S/C15H17NO4/c1-2-12-8-16(9-13(12)14(17)18)15(19)20-10-11-6-4-3-5-7-11/h3-7H,2,8-10H2,1H3,(H,17,18) | InChIKey | HFBYGZWWAMZBID-UHFFFAOYSA-N | SMILES | N1(C(OCC2=CC=CC=C2)=O)CC(CC)=C(C(O)=O)C1 |
| 1-[(benzyloxy)carbonyl]-4-ethyl-2,5-dihydro-1H-pyrrole-3-carboxylic acid Usage And Synthesis |
Uses | 1-[(benzyloxy)carbonyl]-4-ethyl-2,5-dihydro-1H-pyrrole-3-carboxylic acid is a pharmaceutical intermediate compound used in the synthesis of Upadacitinib, a Janus kinase (JAK) inhibitor approved by the FDA for the treatment of various chronic inflammatory conditions such as moderate-to-severe rheumatoid arthritis (RA), psoriatic arthritis, atopic dermatitis, ankylosing spondylitis, Crohn's disease, and ulcerative colitis. |
| 1-[(benzyloxy)carbonyl]-4-ethyl-2,5-dihydro-1H-pyrrole-3-carboxylic acid Preparation Products And Raw materials |
|